UroGen Pharma to Present at the Ladenburg Thalmann 2018 Healthcare Conference

Article Stock Quotes (1)

FREE Breaking News Alerts from StreetInsider.com!

StreetInsider.com Top Tickers, 9/23/2026

1. SPY
2. KBH
3. PATH
4. USO
5. AZO

6. QQQ
7. ORCL
8. RCL
9. ONON
10. CRWV

Get Alerts URGN Hot Sheet

Price: $41.63 -2.64%

Overall Analyst Rating:
SELL (= Flat)

EPS Growth %: +92.8%

Join SI Premium – FREE

RA’ANANA, Israel & NEW YORK--(BUSINESS WIRE)-- UroGen Pharma Ltd. (Nasdaq: URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in the field of urology, with a focus on uro-oncology, today announced that Ron Bentsur, Chief Executive Officer, will present at the Ladenburg Thalmann 2018 Healthcare Conference in New York, NY on Tuesday, October 2, 2018 at 2:30PM Eastern Time.

A live audio webcast of the event will be available on the Investors section of UroGen's website, www.urogen.com. A replay of the webcast will be available on the website for approximately two weeks following the live presentation.

About UroGen Pharma Ltd.

UroGen Pharma Ltd. (Nasdaq: URGN) is a clinical-stage biopharmaceutical company developing advanced non-surgical treatments to address unmet needs in the field of urology, with a focus on uro-oncology. UroGen has developed RTGelâ¢, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs. UroGenâs sustained release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option. UroGenâs lead product candidates, UGN-101 (mitomycin gel for urothelial instillation), formerly known as MitoGelÂ®, and UGN-102 (mitomycin gel for intravesical instillation), formerly known as VesiGelâ¢, are designed to potentially remove tumors by non-surgical means and to treat several forms of non-muscle invasive urothelial cancer, including low-grade upper tract urothelial carcinoma and bladder cancer, respectively. UroGen is headquartered in Raâanana, Israel with U.S. headquarters in New York.